Citations

Showing 10 of 108119 citations.

Identification of lnc RNA s associated with early‐stage breast cancer and their prognostic implications
Rao, Arunagiri Kuha Deva Magendhra , Patel, Krishna , Jyothiraj, Suneetha Korivi, Meenakumari, Balaiah, Sundersingh, Shirley , Sridevi, Velusami , Rajkumar, Thangarajan , Pandey, Akhilesh , Chatterjee, Aditi , Mani, Samson , Pandey, Akhilesh , Gowda, Harsha

Mayo Clinic

Molecular Oncology | April 8, 2019 | Volume: 13 | Issue: 6 | Pages: 1342-1355

10.1002/1878-0261.12489 | PMID 30959550 Get It

Breast cancer is the most common malignancy among women, with the highest incidence rate worldwide. Dysregulation of long noncoding RNA s during the preliminary stages of breast carcinogenesis is poorly understood. In this study, we performed RNA sequencing to identify long noncoding RNA expression profiles associated with early‐stage breast cancer. RNA sequencing was performed on six invasive ductal carcinoma (IDC) tissues along with paired normal tissue samples, seven ductal carcinoma in situ tissues, and five apparently normal breast tissues. We identified 375 differentially expressed lncRNAs (DElncRNAs) in IDC tissues compared to paired normal tissues. Antisense transcripts (~ 58%) were the largest subtype among DE lnc RNA s. About 20% of the 375 DE lnc RNA s were supported by typical split readings leveraging their detection confidence. Validation was performed in n = 52 IDC and paired normal tissue by qRT ‐ PCR for the identified targets ( ADAMTS 9‐ AS 2, EPB 41L4A‐ AS 1, WDFY 3‐ AS 2, RP 11‐295M3.4, RP 11‐161M6.2, RP 11‐490M8.1, CTB ‐92J24.3, and FAM 83H‐ AS 1). We evaluated the prognostic significance of DE lnc RNA s based on TCGA datasets and report that overexpression of FAM 83H‐ AS 1 was associated with patient poor survival. We confirmed that the downregulation of ADAMTS 9‐ AS 2 in breast cancer was due to promoter hypermethylation through in vitro silencing experiments and pyrosequencing.
Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas
Yip, Stephen , Jiang, Bowen , Wang, Wei‐Lien , Lazáry, Áron , Gambarotti, Marco , Zhang, Ming , Sciubba, Daniel M. , Wolinsky, Jean‐Paul , McCarthy, Edward F. , Germscheid, Niccole, Sahgal, Arjun , Gokaslan, Ziya L. , Fisher, Charles G. , Rhines, Laurence D. , Lazary, Aron , Bettegowda, Chetan , Clarke, Michelle J. , Goodwin, C. Rory , Boriani, Stefano , Varga, Péter

Mayo Clinic

Neuro-Oncology | April 8, 2019 | Volume: 21 | Issue: 8 | Pages: 1005-1015

10.1093/neuonc/noz066 | PMID 30976795 Get It

Abstract Background Spinal chordomas, a subtype of primary spinal column malignancies (PSCM), are rare tumors with poor prognosis, and we have limited understanding of the molecular drivers of neoplasia. Methods Study design was a retrospective review of prospectively collected data with cross-sectional survival. Archived paraffin embedded pathologic specimens were collected for 133 patients from 6 centers within Europe and North America between 1987 and 2012. Tumor DNA was extracted and the human telomerase reverse transcriptase (hTERT) promoter was sequenced. The hTERT mutational status was correlated with overall survival (OS) and time to first local recurrence. Results Ninety-two chordomas, 26 chondrosarcomas, 7 osteosarcomas, 3 Ewing’s sarcomas, and 5 other malignant spinal tumors were analyzed. Median OS following surgery was 5.8 years (95% CI: 4.6 to 6.9) and median time to first local recurrence was 3.9 years (95% CI: 2.5 to 6.7). Eight chordomas, 2 chondrosarcomas, 1 Ewing’s sarcoma, and 1 other malignant spinal tumor harbored either a C228T or C250T mutation in the hTERT promoter. In the overall cohort, all patients with hTERT mutation were alive at 10 years postoperative with a median OS of 5.1 years (95% CI: 4.5 to 6.6) (P = 0.03). hTERT promoter mutation was observed in 8.7% of spinal chordomas, and 100% of chordoma patients harboring the mutation were alive at 10 years postoperative compared with 67% patients without the mutation (P = 0.05). Conclusions We report for the first time that hTERT promoter mutations C228T and C250T are present in approximately 8.7% of spinal chordomas. The presence of hTERT mutations conferred a survival benefit and could potentially be a valuable positive prognostic molecular marker in spinal chordomas.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310

10.6004/jnccn.2019.0019 | PMID 30959462 Get It

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, Daniel G. , Thompson, John A. , Albertini, Mark R. , Barker, Christopher A. , Carson, William E. , Contreras, Carlo M. , DiMaio, Dominick J. , Fleming, Martin D. , Freeman, Morganna , Galan, Anjela , Gastman, Brian , Guild, Valerie, Johnson, Douglas B. , Lange, Julie R., Nath, Sameer K., Olszanski, Anthony J. , Ott, Patrick A. , Gupta, Aparna Priyanath , Ross, Merrick I. , Salama, April K.S. , Skitzki, Joseph J. , Sosman, Jeffrey A. , Wuthrick, Evan , McMillian, Nicole R., Engh, Anita M. , Carson, William E , Olszanski, Anthony J , Daniels, Gregory A. , Fields, Ryan C. , Joseph, Richard W. , Swetter, Susan M. , Tanabe, Kenneth K.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 367-402

10.6004/jnccn.2019.0018 | PMID 30959471 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.
Role of Differential Estrogen Receptor Activation in Airway Hyperreactivity and Remodeling in a Murine Model of Asthma
Ambhore, Nilesh Sudhakar , Kalidhindi, Rama Satyanarayana Raju, Loganathan, Jagadish , Sathish, Venkatachalem , Sathish, Venkatachalem

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | April 8, 2019 | Volume: 61 | Issue: 4 | Pages: 469-480

10.1165/rcmb.2018-0321oc | PMID 30958966 Get It

Abstract Evidence suggests that airway hyperresponsiveness (AHR) is a characteristic feature of asthma. Epidemiological studies have confirmed that the severity of asthma is greater in women, suggesting a critical role of female sex steroid hormones (especially estrogen). Very few in vivo studies have examined the role of sex steroid hormones in asthma, and the sequence of events that occur through differential activation of estrogen receptors (ERs) remains to be determined in asthmatic airways. Our recent in vitro findings indicated that ERβ had increased expression in asthmatic airway smooth muscle (ASM), and that its activation by an ERβ-specific agonist downregulated airway remodeling. In this study, we translated the in vitro findings to a murine asthma model and examined the differential role of ER activation in modulating lung mechanics. C57BL/6J male, female, and ovariectomized mice were exposed to mixed allergen (MA) and subcutaneously implanted with sustained-release pellets of placebo, an ERα agonist (4,4′,4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol [PPT]), and/or an ERβ agonist (WAY-200070). We then evaluated the effects of these treatments on airway mechanics, biochemical, molecular, and histological parameters. Mice exposed to MA showed a significant increase in airway resistance, elastance, and tissue damping, and a decrease in compliance; pronounced effects were observed in females. Compared with PPT, WAY treatment significantly reversed the MA-induced changes. The increased mRNA/protein expression of ERα, ERβ, and remodeling genes observed in MA-treated mice was significantly reversed in WAY-treated mice. This novel study indicates that activation of ERβ signaling downregulates AHR and airway remodeling, and is a promising target in the development of treatments for asthma.
Anatomie der Fettkompartimente des Gesichts und ihre Bedeutung für die ästhetische Chirurgie
Lachman, Nirusha , Cotofana, Sebastian

Mayo Clinic

JDDG: Journal der Deutschen Dermatologischen Gesellschaft | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 399-415

10.1111/ddg.13737_g | PMID 30958928 Get It

ZusammenfassungZielIn den letzten zehn Jahren hat sich unser Verständnis der Gesichtsanatomie gewandelt. Neuere minimalinvasive Eingriffe zur Gesichtsverjüngung erfordern bessere anatomische Kenntnisse.Material und MethodenIn dieser narrativen Übersichtsarbeit wird die aktuelle Literatur mit den Erfahrungen der Autoren zusammengefasst und analysiert. Sie resümiert den aktuellen Wissenstand zu oberflächlichen und tiefen fazialen Fettkompartimenten und deren Bedeutung für minimalinvasive Eingriffe am Gesicht. Ein schematisches Modell zum besseren Verständnis der komplexen Anatomie des Gesichts wurde erstellt.ErgebnisseDas Gesicht ist aus den folgenden fünf Schichten aufgebaut: Schicht 1: Haut; Schicht 2: subkutanes Fettgewebe mit Retinacula cutis (aus fibrösem Bindegewebe), Schicht 3: superfizielles muskuloaponeurotisches System (SMAS), Schicht 4: tiefes Fettgewebe und Schicht 5: Periost oder tiefe Faszie. Dieser Aufbau unterscheidet sich je nach Region, insbesondere, wenn die Ligamente in das Modell einbezogen werden. Die fazialen Fettkompartimente sind in den Schichten 2 und 4 lokalisiert. Jede Schicht hat einzigartige Merkmale und spezielle räumliche Beziehungen zu den umgebenden Geweben.SchlussfolgerungenDas neue Konzept des geschichteten Aufbaus erklärt die räumlichen Beziehungen und das funktionale Zusammenwirken der Weichteilgewebe im Gesicht. Die Kenntnis der Schichten sowie der genauen Lage der oberflächlichen und tiefen Fettkompartimente des Gesichts und ihrer Begrenzungen ist entscheidend für die sichere und effektive Durchführung minimalinvasiver Eingriffe am Gesicht.
Deletion of kallikrein 1b5 (Klk1b5) has no impact on fertility in mice
Beedle, My‐Thanh , Herrera, Gerardo B., Tam, Keila K., Winuthayanon, Wipawee , Winuthayanon, Wipawee , Li, Shuai , Herrera, Gerardo G.

Mayo Clinic

Molecular Reproduction and Development | April 8, 2019 | Volume: 86 | Issue: 6 | Pages: 611-613

10.1002/mrd.23145 | PMID 30957940 Get It

Current practices in the delivery of pharmacogenomics: Impact of the recommendations of the Pharmacy Practice Model Summit
Valgus, John , Weitzel, Kristin, Peterson, Josh F. , Formea, Christine M. , Peterson, Josh F , Crona, Daniel James

Mayo Clinic

American Journal of Health-System Pharmacy | April 8, 2019 | Volume: 76 | Issue: 8 | Pages: 521-529

10.1093/ajhp/zxz024 | PMID 31361863 Get It

AbstractPurposeThis report examines and evaluates pharmacogenomics as an emerging science as it relates to the Practice Advancement Initiative and its predecessor the Pharmacy Practice Model Initiative’s consensus statements for optimal pharmacy practice models.SummaryPharmacogenomics is one of many emerging sciences to impact medication management and delivery of patient care. Increasingly, biomarkers are included in drug labeling and can assist pharmacists with personalizing medicine to optimize patient therapies and avoid adverse effects. The 2011 ASHP Pharmacy Practice Model Summit generated a list of 147 consensus statements for optimal pharmacy practice. Of these, 1 statement explicitly describes adjustment of drug regimens based on genetic factors as an essential activity of pharmacist-provided drug regimens, and 9 other statements provide additional support for incorporation of this emerging science into all aspects of patient care provided by pharmacists. We describe 4 institutions that have made significant inroads to implementing pharmacogenomics, to provide a framework and serve as resources for other institutions initiating their own pharmacogenomics implementation journeys.ConclusionThrough prioritized efforts of the pharmacy profession and health care institutions, pharmacogenomics will be disseminated and implemented, and the goal of the Pharmacy Practice Model Initiative’s consensus statements of improving health care using patients’ genetic characteristics will be realized.
Anorectal pressures measured with high‐resolution manometry in healthy people—Normal values and asymptomatic pelvic floor dysfunction
Oblizajek, Nicholas R. , Gandhi, Sangeetha, Sharma, Mayank , Chakraborty, Subhankar , Muthyala, Anjani, Prichard, David O. , Feuerhak, Kelly, Bharucha, Adil E. , Prichard, David , Oblizajek, Nicholas R

Mayo Clinic

Neurogastroenterology & Motility | April 8, 2019 | Volume: 31 | Issue: 7 | Pages: No page available

10.1111/nmo.13597 | PMID 30957382 Get It

AbstractBackgroundHigh‐resolution manometry (HRM) is used to measure rectoanal pressures in defecatory disorders and fecal incontinence. This study sought to define normal values for rectoanal HRM, ascertain the effects of age and BMI on rectoanal pressures, and compare pressures in asymptomatic women with normal and prolonged balloon expulsion time (BET).MethodsHigh‐resolution manometry pressures and BET were measured in 163 asymptomatic healthy participants. Women (96) and men (47) with normal BET were used to estimate normal values and the effects of age/BMI on pressures using a Medtronic 4.2‐mm‐diameter rectoanal catheter.Key ResultsAge is associated with lower resting pressure, higher rectal pressure during evacuation, and a higher rectoanal gradient during evacuation in women and men. In women, the BET is also inversely correlated with age while the BMI is correlated with a higher threshold volume for discomfort and a longer BET. The anal squeeze pressure increment, squeeze duration, and HPZ length are higher in men than women. The rectoanal gradient during evacuation is also lower (ie, more negative) in asymptomatic women with an abnormal than a normal BET.Conclusions & InferencesThese findings provide an expanded database of normal values for anorectal HRM in men and women. Age and sex affect anal resting and squeeze pressures, respectively; rectal pressure during evacuation is also higher in older people. Less than 15% of asymptomatic people have BET >60 seconds, which is associated with manometry features of impaired evacuation.
Right ventricular and pulmonary vascular function indices for risk stratification of patients with pulmonary regurgitation
Egbe, Alexander C. , Miranda, William R. , Pellikka, Patricia A. , Pislaru, Sorin V. , Borlaug, Barry A. , Kothapalli, Srikanth, Ananthaneni, Sindhura, Najam, Maria , Abdelsamid, Mohamed Farouk, Connolly, Heidi M. , Sandhyavenu, Harigopal , Farouk Abdelsamid, Mohamed, Sabbah, Michael S. , Pellikka, Patricia A , Borlaug, Barry A

Mayo Clinic

Congenital Heart Disease | April 8, 2019 | Volume: 14 | Issue: 4 | Pages: 657-664

10.1111/chd.12768 | PMID 30957982 Get It